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Abstract  
Dendritic cells (DC) play a pivotal role in the induction and regulation of immune responses, 
including the induction of cytotoxic T lymphocytes (CTL) responses. These are essential for 
the eradication of cancers and pathogens including HIV and malaria, for which there are 
currently no effective vaccines. New developments in our understanding of DC biology have 
identified the key DC subset responsible for CTL induction, which is now an attractive 
candidate to target for vaccination. These DC are characterized by expression of novel 
markers Clec9A and XCR1, and a specialized capacity to cross-present antigen (Ag) from 
tumors and pathogens that do not directly infect DC. New generation DC vaccines that 
specifically target the cross-presenting DC in vivo have already demonstrated potential in 
preclinical animal models but the challenge remains to translate these findings into clinically 
efficacous vaccines in man. This has been greatly facilitated by the recent identification of 
the equivalent CLEC9A+XCR1+ cross-presenting DC in human lymphoid tissues and 
peripheral tissues that are key sites for vaccination administration. These findings combined 
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with further studies on DC subset biology have important implications for the design of new 
CTL-mediated vaccines.  
 
DC Vaccines for the induction of CTL against pathogens and cancers 
The success of currently available vaccines is reliant on their ability to induce serum 
neutralizing antibodies. However, for the development of prophylactic and therapeutic 
vaccines against cancer and pathogens including HIV, malaria and tuberculosis there is now a 
large body of evidence to suggest that the induction of cytotoxic T cell (CTL) responses are 
important to provide protection and control established disease. Despite intensive efforts to 
develop vaccines designed to induce CTL responses, there are currently no effective vaccines 
for these diseases. Dendritic cells (DC) are the key antigen-presenting cells responsible for 
the initiation of CTL-mediated immune responses against cancers, intracellular pathogens 
and viruses. The existence of multiple DC subsets with specialized functions is now apparent 
in mice but translating this to humans has been a major challenge. Several recent studies have 
provided new insights into the dendritic cell network in human tissues. These findings have 
significant implications for the design of CTL-mediated vaccines.  
The complex network of DC: multiple subsets with specialized functions  
The DC network is comprised of multiple subsets that differ in their ontology, location, 
phenotype and specialised function. The first division, evident in both mouse and man, occurs 
between plasmacytoid DC (pDC) and myeloid DC, the latter also referred to as conventional 
DC (cDC). PDC produce large amount of type I IFN 1, 2 and act as a first line of defence 
against viral pathogens, though their role in the priming T cell responses remains 
controversial 3. By contrast, cDC are considered the “professional” antigen (Ag) presenting 
cells critical for the activation of naïve T cells 4, 5. The cDC are further divided into 
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“lymphoid-resident” DC and “migratory DC”. The lymphoid-resident DC arrive in lymphoid 
organs as blood-borne precursors that develop into immature DC where they monitor the 
blood,  lymphatics or other DC for pathogens5, 6, 7. In the mouse, lymphoid-resident DC are 
further segregated into CD8+ DC and CD8- DC based on their expression of the CD8α chain 
5. The migratory DC do not develop in the lymphoid organs, but in the peripheral sites that 
they then monitor and sample for Ag. In the steady state, and at an increased rate upon 
activation in response to pathogens or host intrinsic signals of damage, migratory DC travel 
to lymphoid tissues 8. During this process they up-regulate their co-stimulatory molecules and 
proceed to directly present their Ag to T cells 9 or share the captured Ag with lymphoid-
resident DC 6. There are multiple subsets of migratory DC depending on the location they 
survey 10, 11. Significant functional specialisations are seen between the CD103-CD11b+ 
(referred to as CD11b+ DC) and CD103+CD11bloDC (referred to as CD103+DC) and the 
Langerhans’ cells (CD207+CD11b+CD103−) 4. Lastly, a separate DC population, termed 
“inflammatory DC”, originates from monocytes and develops rapidly in response to 
inflammation or infection. These DC probably most closely resembles the monocyte-derived 
DC generated in vitro in the presence of GM-CSF/IL-4 12-14. 
Defining cross-presenting DC and their role in CTL-mediated immunity 
Although by definition all cDC are capable of processing and presenting Ag and priming 
naïve T cell responses, only a small subset of migratory and lymphoid-resident cDC 
specialise in “cross-presentation”, that is the ability to present exogenous Ag in the context of 
MHC class I. Typically only endogenous Ag is presented in the context of MHC class I but 
cross-presenting DC sample Ag from other cells, circumventing the need to be directly 
infected by pathogens to acquire their Ag to prime CTL. In the mouse, the lymphoid-resident 
CD8+ DC and migratory CD103+ DC are the main cross-presenting DC and are crucial for the 
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induction of CTL responses against cancers, viruses and other pathogenic infections 15-18. 
Indeed, there is strong evidence that these two DC subsets are closely related. Both CD8+DC 
and CD103+ DC have a similar transcriptional signature 19, require BatF3 15, Id2 20 and IRF8 
18, 20 for development and arise from a common precursor 20. Initially, CD8+DC and CD103+ 
DC were thought to be entirely dependent on Batf3 for development as exemplified by their 
absence in Batf3 deficient mice, which retained all other DC subsets 15, 18, 21. More recent data 
suggests that Batf and Batf2 can compensate for Batf3 22. Despite this, CD8+ DC and CD103+ 
DC are often referred to as Batf3-dependent DC. Delivering Ag and adjuvant directly to these 
DC is an attractive strategy for the induction of CTL and hence being pursued in preclinical 
models 10. Since human DC do not express CD8α, and CD103 is broadly expressed, 
translating the biology of mouse DC to human DC has been problematic. The discovery of 
several novel molecules exclusively expressed by these DC has permitted more refined 
phenotyping and functional insights and, importantly as discussed below, the identification of 
the human equivalents.  
Bridging the gap between mouse and human DC: identification of conserved markers 
In human, cDC have been classically defined as blood-lineage-marker negative, MHC class 
II+ and CD11c+ and are subdivided into CD1c (BDCA-1)+ and CD141 (BDCA-3)+ DC. There 
is now convincing evidence from a number of groups using genomics, phenotypic and 
functional approaches that CD141+ DC in blood and lymphoid tissues are the human 
equivalents of the mouse lymphoid-resident CD8+ DC 23-26. Like their mouse counterpart, 
CD141+ DC are efficient at cross-presentation, express TLR3, and respond to TLR3 ligation 
by producing IFN-λ 27. However, CD141 is not an ideal defining marker since it is widely 
expressed on human cells and entirely absent from all mouse DC. Thus, the requirement for 
conserved markers between species has continued and was only fulfilled with the 
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identification of the C-type-lectin, CLEC9A, the chemokine receptor XCR1, and the nectin-
like protein CADM1 (Necl2). CLEC9A is a receptor for dead cells and a regulator of cross-
priming 28-30, whilst XCR1 and CADM1 play a role in CD8+ T cell stimulation 31, 32. All three 
molecules are expressed on mouse CD8+ DC and the human equivalent CD141+ DC. Clec9A 
and XCR1 are particulalry important as they provide the means to identify the human 
equivalent of the murine migratory CD103+ DC. In the mouse, only the CD8+ DC and 
CD103+ DC express XCR1 19, 33 and both DC subsets express Clec9A 34-37. Importantly, 
human CD141+ DC expressing Clec9A and/or XCR1 have now been identified in lymphoid 
and non-lymphoid tissues, including skin, lung and gut 25, 26, 36, 38, 39. This suggests that the 
Clec9A+XCR1+CD141+DC in peripheral tissues are the human equivalent of the mouse 
Clec9A+XCR1+CD103+ DC, which survey the periphery and traffic to the lymphoid organs. 
Given the high degree of conservation in tissue localization and genomic, phenotypic and 
functional similarities, a unified identity for the cross-presenting DC across multiple tissue 
subtypes and species is now achievable. Since Clec9A and XCR1, in conjunction, are the 
most specific defining markers across tissues and species, we hereafter refer to this 
population of cross-presenting DC as CLEC9A+XCR1+ DC. 
Targeting cross-presenting DC for immunotherapy 
CTL are stimulated by activated DC that have processed and are presenting Ag in the context 
of MHC class I in the lymph nodes. Therapeutic vaccines utilizing peptides, recombinant 
proteins, viral vectors, tumor cells or lysates are “non-targeted” and rely on these agents 
being captured by local DC and transported to the draining lymph node for presentation to T 
cells. In an effort to enhance the amount of tumor Ag presented by DC, an alternative 
approach involved differentiating DC from monocytes in vitro, loading these with Ag and 
adjuvants and injecting these into patients as therapeutic vaccines. Unfortunately, these 
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therapeutic DC-based cancer vaccines are expensive, labour-intensive, require customization 
for each patient, and ultimately have been of limited clinical benefit 40,41. A more efficient 
vaccine strategy is to deliver the Ag directly to DC in vivo. This has been achieved by 
immunizing with monoclonal antibodies (mAb) that recognize cell surface receptors 
expressed on DC and carry antigenic cargo. Targeting Ag to the DC subsets that are ideally 
equipped for cross-presentation and priming of CTL responses would inherently seem 
advantageous. In the mouse, it is the CLEC9A+XCR1+ DC that play a key role in the 
induction of CTL and since their counterpart is conserved in humans, delivering Ag to this 
DC subset via mAb that recognize Clec9A or XCR1 is an attractive vaccine strategy. This is 
now a viable option, firstly due to the development of anti-Clec9A and anti-XCR1 mAb that 
can delivery of Ag specifically to CLEC9A+XCR1+ DC in vivo 33, 42, mediating cross-
presentation and CTL induction 34, 37, 43, 44. Secondly, it is now clear that these cells are 
located in tissues such as skin 38 and lung 36 where vaccine administration (i.e. intradermal or 
intranasal) is not only practical but has been clinically demonstrated to be more effective with 
lower doses of Ag compared to the standard injection routes (i.e. intramuscular, 
subcutaneous) 45, 46. 
Targeting cross-presenting DC in the mouse –what have we learnt? 
In the mouse, extensive work has been published on targeting Ag to DEC-205, a multi-lectin 
receptor expressed at high levels of CD8+ DC (reviewed elsewhere 10). This body of work has 
made two clear observations. Firstly, effective priming of CTL requires the delivery of Ag in 
the presence of DC activation/maturation signals 47, 48 and secondly, targeting the subset of 
DC that cross-present results in superior CD8 T cell responses 49, 50. In the mouse, many other 
receptors have been exploited for the delivery of Ag and these studies have made a number of 
other salient points 51. For example, it is logical to assume that the best receptor for Ag-
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delivery should only be expressed on DC; indeed promiscuous expression by other APC may 
prove detrimental. However, targeting Ag to DEC-205 48, CD36 52, CD11c 53, and Clec12A 
44, 54, all of which are expressed on multiple cell types, induced strong CD8 T cell responses. 
Importantly though, whilst the broad expression patterns of these receptors did not prevent 
the induction of CTL, it was the DC and not the other cells that were responsible for the 
priming of T cell immunity 54-56. Our own data also warns that not all receptors expressed by 
CD8+ DC will automatically be good vaccine targets. In this vein, though DEC-205, Clec9A 
and Langerin were comparable at promoting CD8 T cell responses 57, delivering Ag to 
Clec12A, which is also expressed on CD8+ DC (as well as other DC subsets and non-DC) 
was significantly less effective at promoting cross-presentation 44. The capacity of the 
individual receptor to promote cross-priming is critical when considering it a vaccine target. 
We and others have already confirmed that targeting Ag to Clec9A is extremely effective at 
promoting the priming of CTL 37, 44 and generating protective anti-tumor responses 37. The 
question remaining to be answered is whether XCR1, the other receptor exclusively 
expressed on the cross-priming DC can be used to induce CTL. Since an anti-XCR1 mAb has 
recently been generated 33, 42, it will be possible to compare Ag delivery to these receptors 
and determine which is most effective at promoting the induction of CTL. The last point that 
needs consideration is whether the mAb itself may affect immune outcome. In the case of 
Clec9A, one mAb elicits humoral responses in the absence of adjuvants, whilst another 
requires adjuvant 34, 43, 44, 51. Since neither mAb appears to directly activate DC, it is difficult 
to reconcile these differences and this is the subject of a current collaborative study. 
However, in terms of inducing CTL responses, both of these mAb to Clec9A require co-
administered adjuvants for efficacy 37, 44, clearly indicating this will be the optimal targeting 
protocol for future clinical trials. 
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What is the role of other DC-subsets in anti-tumor and anti-viral immunity? 
In the mouse, the crucial role for Clec9A+XCR1+ DC in the induction of anti-tumoral and 
anti-viral immune responses has been established 15, 18, though the individual contributions of 
migratory versus lymphoid-resident Clec9A+XCR1+ DC  remains unknown. Even less is 
known about the contribution of lymphoid-resident CD8- DC and CD11b+ migratory DC, to 
anti-tumour and anti-viral immunity. There is some evidence that at least some subtypes of 
these DC are specialized at inducing CD4+ T cell responses 9, 58-60. This may be an important 
consideration in vaccine design for maximizing CD4 T helper and humoral immune 
responses. Another important function of migratory CD11b+ cDC may be to transfer Ag to 
lymphoid-resident CLEC9A+XCR1+ DC 6 but the significance of this process in CTL-
mediated immunity is yet to be elucidated. The absence of a unique transcription factor 
defining the CD11b+ cDC subsets makes it difficult to discern their function in vivo. There 
are currently no definitive markers that clearly align the CD11b+ cDC subsets across different 
tissues and species.  
In the mouse, under inflammatory conditions, monocytes can also acquire DC-like features 12 
and effectively cross-present targeted Ag 61. The equivalent of these in vivo-induced 
monocytes-derived DC remain to be identified in humans. Whether these monocytes-derived 
DC can be exploited for Ag-delivery and induction of CTL remains to be determined. 
Ultimately, it is the identification of definitive new markers that will facilitate the translation 
of mouse DC-biology to human DC-biology and identify the role these DC subsets play in 
cross-priming.  
 
Which Adjuvant will be most effective? 
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One of the most crucial lessons of DC clinical trials has been the requirement for DC 
activation in order to generate CTL responses 40,41. This is also a pre-requisite for the 
induction of CTL in mice when Ag is delivered via mAb in vivo 10. Indeed, delivering Ag and 
adjuvant simultanously to DC enhances immunogenicity 62-66. In terms of DC immunotherapy 
this infers that the adjuvant must be delivered to the same DC subset being targeted with Ag. 
TLR ligands such as Poly I:C (TLR3), MPL (TLR4) and CpG (TLR9) have all demonstrated 
efficacy as potent vaccine adjuvants in mice and non-human primates and are now being 
trialed in humans. Poly I:C is particularly effective as an adjuvant for T cell immunization 
that is well-tolerated in humans and elicits a Type I IFN signature that mimics live virus 
infection 67. The study of mouse and human DC have alerted to one important interspecies 
difference, namely whilst all mouse Clec9A+XCR1+ DC express and TLR3, 4, 9 68 and 
respond to these TLR-ligands, human CLEC9A+XCR1+ DC only express TLR3 25,,69. In light 
of this information, poly I:C or its stabilized analog (LC:IC ) is currently one of the most 
attractive adjuvants to incorporate into vaccines aimed at targeting human CLEC9A+XCR1+ 
DC.  
Concluding Remarks and future directions 
The discovery of the Clec9A+XCR1+ cross-presenting DC in mouse and man has provided 
new insights into the induction of CTL responses against viruses and tumors and paves the 
way for rational vaccine designs. Key questions that remain to be answered are: which 
molecule is the best receptor for Ag delivery, which adjuvant is most effective and ultimatley, 
will targeting this DC subset alone be sufficient to generate protective immunity? In this 
regard further characterization of less well defined DC subsets and their role in viral and 
tumor immunity is essential. Though CLEC9A+XCR1+ DC have been analysed in their 
steady-state, quantitative and qualitative changes in response to infection and cancer may 
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affect the ability to therapeutically target these DC in vivo and will need to be carefully 
evaluated in human disease settings. For cancer, in vivo targeting of DC will likely be most 
effective in combination with other agents that overcome the immunosuppressive 
environment such as targeting CTLA4 or PD1, or enhancing “immunogenic” tumor cell death 
with chemotherapeutic agents 70. For priming viral immune responses, DC targeting may be 
more effective when used in combination with other vaccines as a prime-boost strategy, as 
recently shown for the induction of HIV responses using DEC-205 targeting in non-human 
primates 71. Finally, translating promising findings from preclinical animal models into 
effective human vaccines remains a major challenge. The profound advantages of targeting 
DEC-205 in mice were more modest in non-human primate studies 71, 72. However, the first 
proof-of-concept clinical trials using DEC-205 to target DC in vivo in healthy volunteers are 
underway 72 and the results are eagerly anticipated.   
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